Search
for
Sort by
Research 931–960 of 1000+
- Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis
- Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial
- A phase 2a trial of brepocitinib for cicatricial alopecia
- Epigallocatechin-3 Gallate Inhibits STAT-1/JAK2/IRF-1/HLA-DR/HLA-B and Reduces CD8 MKG2D Lymphocytes of Alopecia Areata Patients
- Tofacitinib Treatment in Patients With Active COVID-19 Infection
- JAK1 gain-of-function variant causes alopecia areata, atopic dermatitis, and autoimmune thyroid disease
- 40062 Mini pulse corticosteroid therapy with oral dexamethasone for moderate to severe alopecia areata: a multicentric study
- Incidence Rates of Infections, Malignancies, Thromboembolism, and Cardiovascular Events in an Alopecia Areata Cohort from a US Claims Database
- Spontaneous complete resolution of alopecia totalis post SARS-CoV-2 infection
- Abrocitinib Treatment in Diffuse Alopecia Areata: A Case Report and a Literature Review
- Effectiveness and safety of baricitinib in severe alopecia areata: 48-week results
- Molecular Predictors of Ritlecitinib Efficacy in Alopecia Areata: Role of JAK3-Dependent Inflammation and Follicular Integrity
- Adjunctive Dupilumab Therapy in a Partial Responder to Baricitinib for Alopecia Areata
- 0433 JAK inhibitor halts the progression of acute exacerbation of alopecia areata
- Pediatric and Adolescent Alopecia Areata Treated with JAK Inhibitors: Balancing Efficacy and Safety Across Clinical Trials
- 808 Lichen planus single cell and spatial profiling of cutaneous lichen planus treated with baricitinib
- BH08 Evaluating quality-of-life measures for alopecia: a comparative analysis of Dermatology Life Quality Index and Hospital Anxiety and Depression Scale correlations with disease severity
- Characteristics and Outcomes of Patients on Tofacitinib for Alopecia Areata or Rheumatoid Arthritis: A Retrospective Cohort Study
- Reddit Analysis Reveals Common Questions of Patients with Alopecia Areata about JAK Inhibitors for Hair Loss.
- 153 Effectiveness of OR-101, a next generation highly selective JAK3 inhibitor, in a humanized murine model of alopecia areata
- 1108 Comparison of ruxolitinib and a collagen-targeted PTH-based hair cycle stimulant on hair follicle counts and hair growth in the C3H/HeJ engrafted mouse model of alopecia areata
- Alopecia Areata
- Down‐regulation of Shh in the hair follicles of mice during chemotherapy‐induced hair loss is mediated by the JAK / STAT1 signaling pathway
- Pharmacologic inhibition of JAK-STAT signaling promotes hair growth
- Hair Regrowth Outcomes of Contact Immunotherapy for Patients With Alopecia Areata
- The Role of Interferon-γ in Autoimmune Polyendocrine Syndrome Type 1
- A Case of Topical Ruxolitinib Treatment Failure in Alopecia Areata
- Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
- Effectiveness and safety of baricitinib in patients with severe alopecia areata: a 36-week multicenter real-world experience
- Drugs targeting the JAK/STAT pathway for the treatment of immune-mediated inflammatory skin diseases: protocol for a scoping review